Friday April 26, 2019

New biomarker for breast and prostate cancers found

0
//

cancer-390322_640

New York : Researchers have identified a novel genetic biomarker responsible for the progression of many breast and prostate cancers.

The finding could bolster efforts to better identify patients who respond to certain types of chemotherapy drugs that attack the most aggressive forms of cancer.

“Understanding and identifying biomarkers is a vital step toward cancer research and care,” said lead study author Michael Freeman from Cedars-Sinai Medical Centre in Los Angeles, California, US.

“New profiling strategies exemplified by this study will ultimately improve our ability to treat cancer patients,” Freeman noted.

The newly identified genetic biomarker – diaphanous- related formin-3 or DIAPH3 – participates in a protein interaction that makes cells rigid.

The study found that when this biomarker is lost or lowered, cells become “deformable,” squeezing through tissue spaces, causing disease growth or progression.

The study was published in the journal Scientific Reports.

(IANS)

 

 

Next Story

Research Reveals, Cancer Patients Are More Likely To Use Marijuana

"Medical marijuana legislation has previously been associated with reduction in hospitalisations related to opioid dependence or abuse, suggesting if patients are in fact substituting marijuana for opioid, this may introduce an opportunity for reducing opioid-related morbidity and mortality,"

0
marijuana
The researchers found significantly increased use of marijuana over time -- likely reflecting increased availability due to legislative changes -- but they found stable rates of opioid use. Pixabay

Many cancer patients use marijuana and its usage has increased, a new study suggests. The findings, published in the journal CANCER, indicate 40.3 per cent cancer patients used marijuana within the past year, compared with 38 per cent of respondents without cancer.

“Prospective clinical trials are needed to quantify the efficacy of marijuana in cancer-specific pain as well as the risk of opioid misuse in this patient population,” said co-author Kathryn Ries Tringale from the University of California, San Diego.

drugs
They found patients with cancer were more likely to use prescription opioids than adults without cancer — 13.9 per cent versus 6.4 per cent. Pixabay

For the study, 826 people with cancer were matched to 1,652 controls.

The researchers found significantly increased use of marijuana over time — likely reflecting increased availability due to legislative changes — but they found stable rates of opioid use.

Doctor

“Prospective clinical trials are needed to quantify the efficacy of marijuana in cancer-specific pain as well as the risk of opioid misuse in this patient population,” said co-author Kathryn Ries Tringale from the University of California, San Diego. VOA

They found patients with cancer were more likely to use prescription opioids than adults without cancer — 13.9 per cent versus 6.4 per cent.

Also Read: Risk to Obscure Creature, Highlights Pangolin Seizures in Asia

“Medical marijuana legislation has previously been associated with reduction in hospitalisations related to opioid dependence or abuse, suggesting if patients are in fact substituting marijuana for opioid, this may introduce an opportunity for reducing opioid-related morbidity and mortality,” said lead author Jona Hattangadi-Gluth from the varsity. (IANS)